The Alpha-1 Foundation is a not-for-profit Florida corporation founded in 1995. The Foundation has developed a solid infrastructure to promote research and the development of new therapies for improving the quality of life for those diagnosed with Alpha-1. It has fostered collaborations with investigators throughout the United States and Europe, working closely with the National Institutes of Health (NIH), the Food and Drug Administration (FDA), people affected by Alpha-1 and the pharmaceutical industry to expedite the development of improved therapies.
The Foundation has invested $71 million to support Alpha-1 Antitrypsin Deficiency research and programs at 112 institutions in North America, Europe, the Middle East and Australia. The Foundation participates in industry and government liaison groups and develops strategic alliances with government, industry and other national and international health and research organizations.
Alpha-1 Antitrypsin Deficiency: A Review for Nurse Practitioners
This on-demand accredited activity intends to close knowledge gaps by increasing awareness regarding Alpha-1, which is paramount to increasing the number of identified carriers, provide strategies for diagnosing and treating these patients, therefore preventing further damage to improve patient outcomes and prolong their life span.